Dynamic Glucose-Enhanced MR Imaging

Paech, Daniel; Radbruch, Alexander

doi:10.1016/j.mric.2020.09.009

Cited by 7 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GlucoCEST imaging suffers of low contrast enhancement, hence requiring high magnetic fields to improve the detectability and the sensitivity of this approach [33][34]74]. However, a great deal of effort is putting into sequences and irradiation pulse optimization in order to improve glucoCEST detection [75][76].…”

Section: Discussionmentioning

confidence: 99%

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET

et al. 2021

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) patients have usually poor outcome after chemotherapy and early prediction of therapeutic response would be helpful. [ 18 F]F-FDG-PET/CT acquisitions are often carried out to monitor variation in metabolic activity associated to response to the therapy, despite moderate accuracy and radiation exposure limit its application. The glucoCEST technique relies on the use of unlabelled D-glucose to assess glucose uptake with conventional MRI scanners and is currently under active investigations at clinical level. This work aims at validating the potential of MRI-glucoCEST in monitoring early therapeutic responses in a TNBC tumor murine model. Procedures: Breast tumor (4T1) bearing mice were treated with doxorubicin or dichloroacetate for one week. PET/CT with [ 18 F]F-FDG and MRI-glucoCEST were performed at baseline and after 3 cycles of treatment. Metabolic changes measured with [ 18 F]F-FDG-PET and glucoCEST were compared and evaluated with changes in tumor volumes. Results: Doxorubicin treated mice showed a significant decrease in tumor growth when compared to the control group. GlucoCEST imaging provided early metabolic response after three cycles of treatment, conversely, no variations were detect by in [ 18 F]F-FDG uptake. Dichloroacetate treated mice did not show any decrease either in tumor volume or in tumor metabolic activity as assessed by both glucoCEST and [ 18 F]F-FDG-PET. Conclusions:Early metabolic changes during doxorubicin treatment can be predicted by glucoCEST imaging that appears more sensitive than [ 18 F]F-FDG-PET in reporting on early therapeutic response.These findings support the view that glucoCEST may be a sensitive technique for monitoring metabolic response, but future studies are needed to explore the accuracy of this approach in other tumor types and treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Later on, comparing the glucoCEST signal with [ 18 F]‐FDG autoradiography in a human colorectal tumor mouse xenograft model, provided further support of the view that glucoCEST is specific and provides as sensitive a measure as FDG uptake 16 . Moreover, dynamic glucose enhanced MRI was also used to study malignant brain tumor and blood–barrier breakdown at a clinical level 17,18 . It was also shown that the sensitivity of mapping the glucose concentration in the brain could be increased by assessing the OH proton exchange by means of spin‐lock MRI 19,20 .…”

Section: Introductionmentioning

confidence: 90%

“… 16 Moreover, dynamic glucose enhanced MRI was also used to study malignant brain tumor and blood–barrier breakdown at a clinical level. 17 , 18 It was also shown that the sensitivity of mapping the glucose concentration in the brain could be increased by assessing the OH proton exchange by means of spin‐lock MRI. 19 , 20 Recently, in a detailed study of the exchange rate constant of glucose hydroxyl groups, optimal parameters for in vivo glucoCEST/chemical exchange‐sensitive spin‐lock (CESL) detection at clinical and ultrahigh field strengths were reported.…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo comparison of MRI chemical exchange saturation transfer (CEST) properties between native glucose and 3‐O‐Methyl‐D‐glucose in a murine tumor model

et al. 2021

View full text Add to dashboard Cite

D-Glucose and 3-O-Methyl-D-glucose (3OMG) have been shown to provide contrast in magnetic resonance imaging-chemical exchange saturation transfer (MRI-CEST)images. However, a systematic comparison between these two molecules has yet to be performed. The current study deals with the assessment of the effect of pH, saturation power level (B 1 ) and magnetic field strength (B 0 ) on the MRI-CEST contrast with the aim of comparing the in vivo CEST contrast detectability of these two agents in the glucoCEST procedure. Phosphate-buffered solutions of D-Glucose or 3OMG (20 mM) were prepared at different pH values and Z-spectra were acquired at several B 1 levels at 37 C. In vivo glucoCEST images were obtained at 3 and 7 T over a period of 30 min after injection of D-Glucose or 3OMG (at doses of 1.5 or 3 g/kg) in a murine melanoma tumor model (n = 3-5 mice for each molecule, dose and B 0 field). A markedly different pH dependence of CEST response was observed in vitro for D-Glucose and 3OMG. The glucoCEST contrast enhancement in the tumor region following intravenous administration (at the 3 g/kg dose) was comparable for both molecules: 1%-2% at 3 T and 2%-3% at 7 T. The percentage change in saturation transfer that resulted was almost constant for 3OMG over the 30-min period, whereas a significant increase was detected for D-Glucose. Our results show similar CEST contrast efficiency but different temporal kinetics for the metabolizable and the nonmetabolizable glucose derivatives in a tumor murine model when administered at the same doses.

show abstract

“…The detected signal is proportional to the local concentration change of glucose after intravenous administration. 342 Demonstrations of feasibility of DGE MRI in patients with glioma were performed by Xu et al 343 using CEST and by Schuenke et al 344 , 345 and Paech et al 346 using adiabatically prepared CESL MRI. Glucose contrast enhancement has been reported, especially in areas of disrupted blood-brain barrier (BBB), suggesting major signal contributions from BBB leakage and tissue perfusion.…”

Section: Chemical Exchange-sensitive Magnetic Resonance Imagingmentioning

confidence: 99%

7 Tesla and Beyond

2021

Self Cite

View full text Add to dashboard Cite

Ultrahigh magnetic fields offer significantly higher signal-to-noise ratio, and several magnetic resonance applications additionally benefit from a higher contrast-to-noise ratio, with static magnetic field strengths of B 0 ≥ 7 T currently being referred to as ultrahigh fields (UHFs). The advantages of UHF can be used to resolve structures more precisely or to visualize physiological/pathophysiological effects that would be difficult or even impossible to detect at lower field strengths. However, with these advantages also come challenges, such as inhomogeneities applying standard radiofrequency excitation techniques, higher energy deposition in the human body, and enhanced B 0 field inhomogeneities. The advantages but also the challenges of UHF as well as promising advanced methodological developments and clinical applications that particularly benefit from UHF are discussed in this review article.

show abstract

Dynamic Glucose-Enhanced MR Imaging

Cited by 7 publications

References 40 publications

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F-FDG-PET

In vitro and in vivo comparison of MRI chemical exchange saturation transfer (CEST) properties between native glucose and 3‐O‐Methyl‐D‐glucose in a murine tumor model

7 Tesla and Beyond

Contact Info

Product

Resources

About